Crude HSV-2 rates by target group and country
| Low risk | STD clinic attenders | |||||
|---|---|---|---|---|---|---|
| ANC attenders | Females | Males* | Military | Female | Male | |
| HSV-2 +ve % (95% CI) (mean age, SE) | HSV-2 +ve % (95% CI) (mean age, SE) | HSV-2 +ve % (95% CI) (mean age, SE) | HSV-2 +ve % (95% CI) (mean age, SE) | HSV-2 +ve % (95% CI) (mean age, SE) | HSV-2 +ve % (95% CI) (mean age, SE) | |
| *Blood donors (Brazil, Estonia, India, and Sri Lanka), HIV sentinel surveillance participants (Morocco), adult hospital inpatients (Sri Lanka). | ||||||
| Brazil | 29.3 (24.9 to 33.8) (24.9 years, 0.35) | 42.9 (32.1 to 54.1) (34.9 years, 1.02) | 25.9 (21.6 to 30.2) (37.4 years, 0.51) | |||
| Estonia | 23.8 (20.8 to 26.8) (26.7 years, 0.21) | 21.1 (17.7 to 24.4) (30.8 years, 0.50) | 10.8 (8.0 to 13.7) (30.2 years, 0.50) | |||
| India | 7.9 (6.3 to 9.7) (24.9 years, 0.1) | 14.6 (6.1 to 27.8) (30.9 years, 1.39) | 10.2 (7.2 to 13.1) (31.4 years, 0.42) | |||
| Morocco | 12.9 (11.3 to 14.5) (27.4 years, 0.18) | 9.2 (7.1 to 11.8) (29.3 years, 0.33) | 6.5 (4.7 to 8.6) (25.2 years, 0.29) | |||
| Sri Lanka | 8.3 (6.5 to 10.5) (27.1 years, 0.21) | 21.2 (18.1 to 24.3) (40.0 years, 0.61) | 14.1 (12.4 to 15.8) (35.2 years, 0.34) | 49.3 (43.4 to 55.4) (33.0 years, 0.63) | 33.0 (28.4 to 37.6) (33.3 years, 0.59) | |